Back to Search
Start Over
No reduction of HCV viral load in HIV patients co-infected with HCV genotype 1 during a 30days course of nitazoxanide monotherapy
- Source :
- Antiviral Research. 92:497-499
- Publication Year :
- 2011
- Publisher :
- Elsevier BV, 2011.
-
Abstract
- There are two new drugs approved and several in development for treatment of chronic HCV; among them nitazoxanide (NTZ). Twelve HIV/HCV genotype 1 co-infected patients were enrolled prospectively to receive a 30 days course of oral NTZ 500 mg bid. This therapy was well tolerated in this group of HIV patients co-infected with HCV genotype 1. Nevertheless no changes in HCV viral load were observed during treatment in none of the patients evaluated. This data suggests that despite the promising results reported for HCV genotype 4 mono-infected patients, NTZ exhibit poor activity as monotherapy in HIV/HCV co-infected patients with genotype 1.
- Subjects :
- Adult
Male
medicine.medical_specialty
Genotype
Hepacivirus
Human immunodeficiency virus (HIV)
HIV Infections
Pilot Projects
medicine.disease_cause
Antiviral Agents
Gastroenterology
Hcv genotype 1
Virology
Internal medicine
parasitic diseases
medicine
Humans
Treatment Failure
Pharmacology
biology
Coinfection
business.industry
virus diseases
Nitazoxanide
Hepatitis C
Hepatitis C, Chronic
Middle Aged
Viral Load
Nitro Compounds
medicine.disease
biology.organism_classification
digestive system diseases
Thiazoles
Hiv patients
Female
business
Viral load
medicine.drug
Subjects
Details
- ISSN :
- 01663542
- Volume :
- 92
- Database :
- OpenAIRE
- Journal :
- Antiviral Research
- Accession number :
- edsair.doi.dedup.....8f8d1b86a890209a3cd33f6473c27c6d